Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest tumor Stories

2014-04-07 12:47:39

A new genetic "signature" to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna will hear today (Saturday). Professor Robert Bristow will tell the conference that although surgery and precision radiotherapy are the mainstays of treatment for cancer that is confined to the prostate, the cancer...

2014-04-07 12:30:02

LONDON, April 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:2014 Opportunities in the US Clinical Chemistry and Immunodiagnostics Market"2014 Opportunities in the US Clinical Chemistry and Immunodiagnostic Market" is a new strategic analysis of major business opportunities emerging in the US clinical chemistry and immunodiagnostic markets during the next five years. The report explores future trends in the US market; provides estimates of the specimen,...

2014-04-04 23:31:28

St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project finds TP53 gene is altered in nearly all osteosarcomas; results help explain how tumors withstand radiation therapy. Memphis, Tenn. (PRWEB) April 03, 2014 The St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project found mutations in the tumor suppressor gene TP53 in 90 percent of osteosarcomas, suggesting the alteration plays a key role early in...

2014-04-04 12:35:32

Using magnetically controlled nanoparticles to force tumor cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden. "The clever thing about the technique is that we can target selected cells without harming surrounding tissue. There are many ways to kill cells, but this method is contained and remote-controlled", said Professor Erik Renström. The point of the new technique is that it is...

2014-03-28 08:26:18

IRVING, Texas, March 28, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, continues to enhance its industry-leading comprehensive tumor profiling service, Caris Molecular Intelligence(TM), now capable of providing an industry-leading 51 drug target associations, including exciting new immunologically-based drug targets. Through these enhancements, Caris Molecular Intelligence will now provide...

2014-03-27 12:30:42

DETROIT, March 27, 2014 /PRNewswire/ -- Patients at Henry Ford Hospital now have a new cancer treatment available that offers an alternative cancer surgery, without the incision or hospital stay, treating patients in 15 minutes or less and returning them to their everyday lives. http://photos.prnewswire.com/prnvar/20140327/DE92316 The Edge(TM) Radiosurgery Suite is designed to perform advanced, non-invasive cancer procedures anywhere in the body - including the brain, spine, head and neck,...

2014-03-26 23:01:48

Patients at Henry Ford Hospital now have a new cancer treatment available that offers an alternative cancer surgery, without the incision or hospital stay, treating patients in 15 minutes or less and returning them to their everyday lives. Detroit, Michigan (PRWEB) March 26, 2014 DETROIT – Patients at Henry Ford Hospital now have a new cancer treatment available that offers an alternative cancer surgery, without the incision or hospital stay, treating patients in 15 minutes or less and...

2014-03-26 16:15:10

In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy – delivered directly through a tumor's blood supply – is working. The investigators say their findings, to be presented March 22-27 in San Diego at the annual meeting of the Society of Interventional Radiology, are the first "proof of principle"...

2014-03-26 16:11:46

A breast cancer therapy that blocks estrogen synthesis to activate cancer-killing genes sometimes loses its effectiveness because the cancer takes over epigenetic mechanisms, including permanent DNA modifications in the patient's tumor, once again allowing tumor growth, according to an international team headed by the University of Pittsburgh Cancer Institute (UPCI). The finding warrants research into adding drugs that could prevent the cancer from hijacking patients' repressive gene...

2014-03-26 11:23:23

Presentations at the 4th European Lung Cancer Conference A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress. For decades, scientists and doctors thought immunotherapy –treatments that harness the immune system to fight a disease-- was of marginal benefit in lung cancer, says Jean-Charles Soria, Institute Gustave Roussy in Paris, France. However a...